This page is educational and non-prescriptive. It summarizes published research on human menopausal gonadotropin and does not recommend any use of it.
Evidence status
hMG sits at the approved-medicine end of the evidence spectrum. It is a prescription fertility drug used in reproductive endocrinology for decades, with randomized comparisons against recombinant FSH in assisted reproduction and published outcome data on pregnancy rates. Very little about it is speculative—which makes it a useful reference point for what a mature evidence base looks like next to the experimental compounds elsewhere in this catalog.
The interesting question in the hMG literature is not whether it works, but how it differs from the recombinant alternatives that were expected to replace it.
What hMG actually contains
hMG is purified from the urine of postmenopausal women and carries both follicle-stimulating hormone and luteinizing hormone activity, in contrast to recombinant FSH preparations that supply FSH alone. A drug profile in Clinical Drug Investigation (PMID 30264288) reviews the highly purified formulation marketed as Menopur and notes that this compositional difference produces a measurably different endocrine profile from rFSH—differing serum levels of FSH, androgens, and estradiol during stimulation.
That is the mechanistic reason the two products behave differently in trials, and it is why "gonadotropin" is not a single interchangeable category.
Head-to-head evidence in IVF
For controlled ovarian stimulation in women undergoing IVF or ICSI, the same review summarizes the comparative findings:
- hMG matched rFSH on pregnancy rates, the endpoint that matters clinically.
- It achieved those rates while yielding fewer oocytes than rFSH.
- Some measures of embryo quality improved with hMG in the IVF setting—but not in ICSI.
- Adding highly purified urinary FSH to hMG produced reproductive outcomes similar to hMG alone.
- Compared with rFSH, hMG was associated with a less pronounced follicular response and a lower risk of ovarian overstimulation.
The oocyte-yield finding is worth dwelling on, because it demonstrates how a surrogate endpoint can diverge from the outcome patients care about. More eggs retrieved did not translate into more pregnancies. A study reporting only oocyte counts would have made rFSH look clearly superior; one reporting pregnancy rates does not.
Ovulation induction and the thinner data
For ovulation induction in anovulatory infertility, the review is explicit that the data for hMG are limited. What exists suggests ovulation rates may be comparable to rFSH plus recombinant LH in WHO type 1 anovulation, and to rFSH alone in type 2 anovulation (PMID 30264288). "May be as good as" reflects the strength of the underlying evidence accurately—these are smaller comparisons than the IVF literature, and the approved-drug status of hMG rests more heavily on the assisted-reproduction data.
hMG is administered under prescription with cycle monitoring, because the dose-limiting risks—ovarian hyperstimulation syndrome and multiple pregnancy—are managed by ultrasound and hormone surveillance rather than by the dose alone.
Reading this literature
Two habits make the gonadotropin literature easier to read. First, check which endpoint is being reported: oocytes retrieved, embryos, clinical pregnancy, and live birth are four different numbers, and products can rank differently on each. Second, check the population, since WHO type 1 anovulation (a hypothalamic-pituitary deficit) and type 2 (normogonadotropic, typically PCOS) respond differently to the same drug. Trial results in one group are not transferable to the other.